Welcome to our dedicated page for Processa Pharmaceuticals news (Ticker: PCSA), a resource for investors and traders seeking the latest updates and insights on Processa Pharmaceuticals stock.
Processa Pharmaceuticals, Inc. (PCSA) generates a steady flow of news as a clinical-stage pharmaceutical company developing Next Generation Cancer (NGC) therapies and advancing select non-oncology programs. News coverage for PCSA commonly centers on its lead asset NGC-Cap (PCS6422 plus capecitabine) in advanced or metastatic breast cancer, where the company reports on Phase 2 trial enrollment milestones, interim analyses, and emerging safety and pharmacokinetic data.
Investors following PCSA news can expect detailed updates on clinical trial progress, including randomized Phase 2 study design features, preliminary findings on cancer-killing metabolite exposure, and comparative safety versus standard capecitabine monotherapy. Releases have highlighted how NGC-Cap may increase exposure to active metabolites while reducing toxic catabolites such as FBAL, along with observations on side-effect profiles like hand-foot syndrome.
Beyond oncology, Processa news also covers its rare disease and gastrointestinal programs, such as PCS499 in focal segmental glomerulosclerosis (FSGS) and PCS12852 for gastroparesis and related gastrointestinal motility disorders. Announcements have included acceptance of abstracts for major meetings like ASN Kidney Week and the signing of a binding term sheet granting Intact Therapeutics an exclusive option to license PCS12852, with associated milestone, royalty, and equity terms.
PCSA news items frequently address capital markets and corporate strategy, including public offerings, private placements, reverse stock split approvals and implementation, and Nasdaq listing compliance updates. The company has also disclosed its evaluation of corporate cryptocurrency treasury strategies as part of its financial planning. In addition, Processa regularly announces participation in high-profile industry events such as the BIO International Convention, the American Society of Clinical Oncology (ASCO) Annual Meeting, and the J.P. Morgan Healthcare Conference, where management meets with investors and potential partners.
By monitoring this news feed, readers can track how Processa’s NGC platform, pipeline decisions, partnership activities, and financing events evolve over time, all based on the company’s own press releases and regulatory disclosures.
Processa Pharmaceuticals (NASDAQ: PCSA) has appointed Michael Floyd as Chief Operating Officer. Floyd, a serial entrepreneur with extensive experience in life sciences, aims to enhance Processa's operational efficiency and long-term strategic direction. His prior leadership roles include CEO at Arpida Ltd. and co-founder of Elion Oncology, where he contributed to the development of oncology products. With a track record of successful drug development and regulatory approval, Floyd's addition is expected to strengthen investor relations and help achieve key milestones in the company's pipeline over the next 12-18 months.
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) announced the closing of its underwritten public offering of 4,800,000 shares of common stock at $4.00 per share, raising approximately $19.2 million. The offering was managed by Craig-Hallum Capital Group and The Benchmark Company, with National Securities Corporation as a co-manager. Funds from the offering will support the development of drug products aimed at improving the survival and quality of life for patients with high unmet medical needs. This follows the effective registration statement filed with the SEC on October 1, 2020.
Processa Pharmaceuticals, Inc. (OTCQB: PCSA; Nasdaq: PCSA) announced an underwritten public offering of 4,800,000 shares of common stock at $4.00 per share, targeting gross proceeds of approximately $19.2 million. The offering is set to close on October 6, 2020, following the approval for the company's common stock to trade on the Nasdaq Capital Market effective October 2, 2020. Proceeds will be utilized for clinical trials and general corporate purposes, backed by a registration statement filed with the SEC.